Abbott will be trying its hand in the growing field of intravascular lithotripsy, with a clinical study to examine an unnamed ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Surrozen is discontinuing its sole clinical-stage candidate and pivoting to its preclinical ophthalmology pipeline after the ...

After outlining plans nearly one year ago to take 23andMe private—and submitting multiple offers—co-founder and CEO Anne ...

Mira Pharmaceuticals is making moves in weight loss and smoking cessation. The biotech is trying to buy Skny Pharmaceuticals ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that ...

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the ...

Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

Ultimately, Chimerix’s board went with Jazz’s offer due to its cash payable nature and the recent downward trend in biopharma ...

At its annual artificial-intelligence-focused GTC conference in San Jose, Nvidia outlined several collaborations with medtech ...

As the U.S. cuts federal research funding and infrastructure, European countries are strategizing ways to attract top ...